Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 7 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

5Total
Not Applicable (2)
Early P 1 (1)
P 2 (2)

Trial Status

Recruiting4
Not Yet Recruiting2
Suspended1

Clinical Trials (7)

Showing 7 of 7 trials
NCT05730283Phase 2RecruitingPrimary

Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin

NCT07364747Phase 2Recruiting

Protective Effect of Acetylcysteine Against Cisplatinum-Induced Ototoxicity: A Randomized Controlled Trial

NCT05936034Not ApplicableRecruiting

Comparative Study of the Quality of Life of Patients Suffering From OTOTOXICITY Due to Chemotherapy Based on Platinum Salts Fitted With a Hearing Aid Compared to Those Not Fitted.

NCT05756660Early Phase 1SuspendedPrimary

Sodium Thiosulfate Otoprotection During Salvage Cisplatin Therapy

NCT06957132Not ApplicableNot Yet RecruitingPrimary

Analysis of Risk Factors for Hearing Loss in Survivors of Cancer Occurred During Childhood, Adolescence or Young Adulthood

NCT06929468Not Yet Recruiting

Cisplatin-induced Cochlear and Vestibular Damage in Head and Neck Cancer

NCT06490029RecruitingPrimary

Diagnostic of Various Ototoxicity Induced by Cancer Treatment

Showing all 7 trials

Research Network

Activity Timeline